Search
Close this search box.

Xenetic Biosciences Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

“Scripps has continued to be a valued partner of ours and we are pleased to extend our collaboration agreement to further explore the potential of our DNase-based oncology platform. We are grateful we are able to continue to leverage the knowledge and expertise of the team at Scripps to potentially expand and broaden the utility of our proprietary platform technology,” commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.

Share:

More News

“The initiation of patient dosing in our Phase 2 trial of Ropidoxuridine for the treatment of patients with glioblastoma is a significant milestone for both Shuttle Pharma and the thousands of patients with brain tumors who currently lack effective therapies,” commented Shuttle Pharma’s Chairman and CEO, Anatoly Dritschilo, M.D. “The

“To our knowledge, Multikine is the only neoadjuvant immunotherapy that has shown overall survival benefit in the low and negative PD-L1 head and neck cancer population. This underscores the critical importance of having reached an agreement with the FDA on the method for identifying and selecting patients with low PD-L1

“We have decided to forgo future development of NKX019 in non-Hodgkin lymphoma. In reviewing the clinical data from the latest cohort of patients with large B-cell lymphoma and the evolving treatment landscape, Nkarta will focus its efforts on autoimmune diseases, where we believe NKX019 has potential to transform patient care.”,

“We believe the data from the recently published ASH abstracts continues to differentiate anito-cel’s clinical profile as a potentially best-in-class treatment option for multiple myeloma patients,” said Rami Elghandour, Arcellx’s Chairman and Chief Executive Officer. “The 30.2-month median progression-free survival demonstrated in our Phase 1 study in a challenging patient